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T regulatory cells and the control of alloimmunity:
from characterisation to clinical application
Joanna Wieckiewicz, Ryoichi Goto and Kathryn J WoodT regulatory cells (Treg) play an important role in the induction
and maintenance of immunological tolerance. Recent findings
in experimental transplant models combined with the
development of functional reporter mice have opened new
avenues to study Treg biology and their therapeutic potential. In
particular, recent advances in understanding Treg function and
lineage stability revealed unexpected plasticity of this lineage.
Nevertheless, pre-clinical and pilot clinical trials using Treg
cells as cellular therapies have been initiated suggesting the
safety and feasibility of such treatment.
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Introduction
The appropriate balance between effector and T regu-
latory cells (Treg) is indispensable for the maintenance of
self-tolerance and of functional immune responses in
vivo. In the transplant setting, numerous findings during
the last 25 years have demonstrated the importance and
therapeutic potential of Treg in the active control of
rejection responses. Although the existence of various
cell populations with regulatory/suppressive activity, such
as IL-10 secreting Tr-1 cells, CD28CD8+ cells or B
regulatory cells, has been demonstrated, in this review
we will focus on classical CD25+CD4+ Treg cells.
Treg mediate suppressive effects by several mechanisms
including anti-inflammatory cytokines (IL-10, TGF-b
and IL-35), direct cytotoxic effect (granzyme B and
galectin-1), metabolic disruption (adenosine production
and IL-2 deprivation) and modulation of dendritic
cell function (CTLA-4, LAG3 and IDO induction) as
discussed in [1]. Numerous regulatory mechanisms
Open access under CC BY license.Current Opinion in Immunology 2010, 22:662–668described to date suggest that multiple, redundant mech-
anisms are required for optimal Treg function in vivo.
Treg can be divided into two populations: thymic-derived
naturally occurring CD25+CD4+ cells (nTreg) [2] and
induced or adaptive Treg (iTreg) that are either differ-
entiated from CD25CD4+ nonregulatory cells or
expanded from CD25+CD4+ cells in response to the
antigen [3]. These cells differ in origin, antigen experi-
ence, methylation patterns of the key transcription factor
FoxP3 and suppressive mechanisms. Recently, the differ-
ential expression of transcription factor Helios has been
attributed to thymic-derived nTregs and proposed as a
marker to differentiate between nTregs and iTregs [4].
Both nTreg and iTreg have been demonstrated to play an
important role in transplant tolerance.
In this review, we explore recent advances in understand-
ing Treg function and lineage stability and its impact on
tolerance induction protocols. Next, we focus on the
current attempts to expand human Treg for clinical
application as a cellular therapy in organ and cell trans-
plantation. Finally, we discuss the arising or potential
issues relating to the therapeutic application of Treg and
proposed solutions.
FoxP3 expression in Treg
Expression of the transcription factor FoxP3 is essential
for the development and function of Treg [5,6]. It was
demonstrated that ectopic expression of Foxp3 in con-
ventional T cells was sufficient to confer suppressive
activity, repress IL-2 and IFNg production and upregu-
late Treg-associated molecules such as CTLA-4 and
GITR [2,7]. Furthermore, expression of FoxP3 in mature
Treg is necessary for the maintenance of Treg-specific
transcription profile and of Treg function [8].
Epigenetic regulation of FoxP3 expression
Several epigenetic markers, such as histone acetylation
and methylation, and cytosine residue methylation in
CpG dinucleotides, have been reported at the Foxp3
locus [9]. In particular, a unique CpG-rich island within
an evolutionarily conserved region upstream of exon 1,
named TSDR (Treg-specific demethylation region), was
demonstrated to be unmethylated in natural Treg but
heavily methylated in other CD4+ T cells [10,11].
Demethylation of these CpG sites resulted in strong
and stable induction of FoxP3. In human, upon in vitro
expansion of Treg, CpG methylation increased correlat-
ing with loss of FoxP3 expression and emergence ofwww.sciencedirect.com
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CD45RA+FoxP3+ naı¨ve Treg showed no increase in
CpG methylation after 3-week culture, whereas
CD45RAFoxP3+ memory-like Treg from the same
donors lost CpG demethylation status and converted into
non-Treg cells. Recent advances in our understanding of
the complex regulation of FoxP3 expression have led to
new methods of analysing Treg based on quantitative
DNA methylation analysis of FoxP3 locus [13], which
may add a useful test for quality assessment of ex vivo
manipulated Treg cells.
Treg lineage stability
FoxP3 epigenetic analysis and the development of func-
tional reporter mice questioned the dogma of natural
Treg lineage stability. An elegant study by Zhou et al.
examined the stability of Treg cells by tracing cells that
induced and downregulated FoxP3 during their life span
[14]. The authors found that cells that at some point
expressed FoxP3 and lost its expression shared their TCR
repertoire both with FoxP3+ Treg cells and with conven-
tional T cells suggesting that they originated from both
nTreg and iTreg. These ‘ex-Treg’ had an activated-
memory phenotype and produced pro-inflammatory cyto-
kines. Notably, an autoimmune microenvironment
favoured loss of FoxP3, and ‘ex-Treg’ cells from diabetic
mice were able to transfer diabetes [14]. Notably for the
transplant setting, it was also demonstrated that some
peripheral FoxP3+CD4+ cells lose their FoxP3 expression
and start producing IFNg and IL-17 after transfer to a
lymphopenic host [15].
Cellular therapy with Treg
Mouse pre-clinical models
Many strategies exist for the in vivo or ex vivo generation
and/or expansion of Treg. The most common in vivo
approaches are based on the fact that exposure to antigen
increases Treg frequency and/or potency by either
expanding naturally occurring Treg or inducing the
generation of adaptive Treg from cells that do not origin-
ally possess regulatory activity [16]. Generation of Treg
can be achieved by attenuation of activating signals
during antigen presentation. In the mouse, donor-specific
transfusion (DST) combined with a nondepleting anti-
CD4 antibody generates CD25+CD4+ cells able to pre-
vent skin graft rejection [17]. Moreover in vitro culture of
mouse CD4+ or CD25CD4+cells in the presence of
alloantigen and anti-CD4 antibody results in the enrich-
ment of CD62L+CD25+ cells effective in controlling graft
survival [18]. Interestingly, conditioning of CD4+ cells in
the presence of interferon-g (IFN-g) and immature DC
can also generate FoxP3+ cells that are able to protect
both skin and islet transplants from rejection [19,20].
Notably, alloantigen-reactive Treg from in vivo tolerised
mice demonstrate increased levels of IFN-g production
transiently after antigen-specific reactivation through T
cell receptor [21]. In vivo, IFNg produced locally wherewww.sciencedirect.comthe Treg are present, the draining lymph nodes and the
graft [22], creates a microenvironment that influences
the function of other cells in the vicinity, including the
Treg themselves where evidence for the activation of
IFNg signalling pathways has been reported [21].
Another approach to enrich Treg in vivo is to create Treg-
favouring conditions. In the transplantation setting,
patients are treated with diverse immunosuppressive
drug combinations, which may have a different impact
on Treg. It was demonstrated that calcineurin inhibitors
(CNI), especially cyclosporine A, are detrimental to Treg,
whereas the mTOR inhibitor rapamycin was shown to be
beneficial for Treg both in terms of in vivo generation and
function in mouse models [23] and in in vitro cultures of
human Treg [24]. It was recently demonstrated that
adoptive transfer of a low number of alloantigen-specific
Treg under a cover of low dose of rapamycin induced
long-term survival of heart transplant in unmanipulated
host, an outcome otherwise difficult to obtain [25]. Inter-
estingly, in terms of alloantigen-specificity of Treg two
recent papers have independently demonstrated that
regulatory cells specific for both directly (by donor
APC) and indirectly (by host APC) presented alloantigens
prolonged graft survival with substantially greater efficacy
thanTreg with only direct anti-donor specificity [26,27].
Noteworthy, successful attempt to achieve long-term
acceptance of islet allografts without immunosuppression
was demonstrated by Webster et al. who in vivo expanded
Treg by injecting mice with IL-2/anti-IL-2 monoclonal
antibody complexes [28].
Human Treg
Human Treg are currently less well characterised and
understood than mouse Treg, so a thorough understand-
ing of their biology is vital before clinical applications can
be initiated. It is also important to highlight that there are
substantial differences between human and mouse Treg;
most notably the differences in FoxP3 expression be-
tween mouse and human. In human, FoxP3 is also
expressed by activated nonregulatory T cells as well as
byTreg, and activated nonregulatory cells also upregulate
CD25 expression. Thus not all CD25+FOXP3+CD4+ will
be genuine Treg and therefore isolation strategies based
on CD25hi/+CD4+ are likely to be imperfect. Other mar-
kers are therefore needed to enrich Treg from human
peripheral blood mononuclear cells. Recently, it has been
demonstrated that CD127loCD25+CD4+ T cells are
characterised by a higher percentage of FoxP3+ cells with
a more pronounced suppressive capacity [29,30]. Expan-
sion of CD127loCD25+CD4+ cells resulted in high yield
of regulatory cells which maintained high FoxP3 expres-
sion [31]. Importantly, as we recently demonstrated
in a clinically relevant humanised model of transplant
arteriosclerosis, ex vivo expanded CD25hiCD4+ and
CD127loCD25+CD4+ Treg cells have been very effective
in inhibiting vasculopathy, with CD127loCD25+CD4+Current Opinion in Immunology 2010, 22:662–668
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Treg [32]. Interestingly, another study subdivided Treg
into two subtypes: resting naı¨ve CD25+CD45RA+FoxP3lo
and activated CD25hiCD45RAFoxP3hi regulatory cells.
A third population of FoxP3+ cells phenotyped as
CD25+CD45RAFoxP3lo was demonstrated to consist
of cytokine-secreting, non-suppressive cells [33]. Nota-
bly, whereas both regulatory subpopulations were highly
suppressive in vitro, only resting Treg were able to
proliferate in vitro and in vivo, converting into activated
CD45RA negative Treg.
A number of different strategies for the isolation/enrich-
ment of human Treg have been described in the litera-
ture, but to date there is no consensus as to which strategy
produces the optimal population for use in cell therapyFigure 1
Steps in preparation and clinical application of Treg cells. In transparent box
therapy. IS—immunosuppression; GMP—good manufacturing practices.
Current Opinion in Immunology 2010, 22:662–668applications. The critical steps and the questions awaiting
answers in the process of developing clinically approved
Treg cellular therapy are outlined in Figure 1.
Clinical application of human Treg
One of the obstacles in the implementation of clinical
protocols using Treg is their low frequency in the per-
ipheral blood leading to the need for ex vivomultiplication
of the cells prior to their use in vivo. The most commonly
used expansion protocol at present is based on stimulation
by anti-CD3/anti-CD28 beads in the presence of high
doses of recombinant IL-2, supplemented in some pro-
tocols with rapamycin. This protocol results in the effi-
cient expansion of polyclonal Treg, generating sufficient
numbers of cells for cellular therapy [34]. However, the
expansion is antigen non-specific without any enrichmentes questions awaiting answers in the process of developing Treg cellular
www.sciencedirect.com
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application, is the concept of expanding or generating
antigen-specific Treg, in the setting of transplantation,
donor alloantigen-reactive Treg. Interestingly, human
Treg expanded with allogeneic PBMC, were found to
be more suppressive in vitro than polyclonaly-driven cells
and, surprisingly, expanded at a similar rate as polyclo-
naly-stimulated cells [35].
Clinical trials
There are several ongoing clinical trials with the appli-
cation of Treg cellular therapy. To date regulatory cells
have been adoptively transferred into haematopoietic
stem cell transplant (HSCT) recipients in Germany,
USA and Italy [36]. In one of such trials, led by Matthias
Edinger from Regensburg, Germany, freshly isolated
bead-selected donor Treg were infused into HSCT reci-
pients. So far nine patients have been included in the
study with no side effects (M. Edinger, personal com-
munication). In a study led by Massimo Martelli, 22
patients were inoculated with freshly isolated donor Treg
followed by infusion of haematopoietic stem cells and
donor conventional T cells. This strategy improved
immune recovery after HSCT without causing graft ver-
sus host disease (GVHD) (Di Ianni et al., 51st ASH
Annual Meeting and Exposition, New Orleans, LA,
December 2009). Another clinical trial in the University
of Minnesota, USA, led by Bruce Blazar and co-workers,
used ex vivo expanded bead-enriched, third-party, par-
tially HLA-matched Treg cells from umbilical cord blood
(UCB). These UCB Treg cells were administered into
myeloablated or nonmyeloablated recipients of two unre-
lated UCB units [36].
Whereas aforementioned studies utilised Treg to prevent
GVHD, Trzonkowski et al. [34] have reported their
findings from two patients with GVHD who were
treated with anti-CD3/anti-CD28 bead expanded
CD25+CD127lo Treg. One of the patients, with chronic
GVHD, responded to the therapy with alleviation of the
symptoms and reduction of immunosuppression. How-
ever, in the case of the second patient with acute, grade IV
GVHD, only transient improvement was observed. Nota-
bly, in the case of the patient treated successfully with
cellular Treg therapy, only 1  105 Treg cells/kg body
weight was sufficient to achieve clinical improvement.
Published reports and unpublished results from other
ongoing studies indicate that Treg cellular therapy is
proving to be effective in clinical situations. Currently,
further clinical studies are being planned to apply Treg
therapy in solid organ transplantation.
Questions arising
IL-17 production by FoxP3+ cells and Treg lineage
stability
The ability of in vitro expanded Treg to convert into
cytokine producing, nonregulatory cells upon prolongedwww.sciencedirect.comTCR stimulation [12] has led to concerns about the
efficacy and safety of ex vivo Treg expansion protocols.
Importantly, it was demonstrated that a proportion of
circulating Treg have the capacity to secrete IL-17 and
express RORgt [37,38]. These IL-17 producing cells are
of memory phenotype and express CCR6, a marker
associated with Th17 cells. Interestingly, some authors
have shown that IL-17 producing CCR6+ Treg are as
equally suppressive as CCR6 Treg [37,38], whereas
others demonstrated a loss of suppressive function in
FoxP3+IL-17+ clones after strong TCR stimulation in
the presence of APC [39]. Although the function and
regulatory properties of these cells in vivo are still deba-
table, the possibility that they may elicit unwanted
responses when transferred to patients cannot be
excluded. However, several markers of ‘true’ Treg have
been described such as IL-1R2, LAP and GARP that may
allow additional post-expansion purification steps to be
introduced into clinical protocols to reduce the risk of
introducing cells that do not have regulatory function
[40,41]. Alternatively, the use of a pure, conversion
resistant Treg subpopulation (CD25+CD45RA+CD127lo)
as a starting population for expansion [12] would also
reduce any safety concerns.
Another way to prevent conversion into Th17 cells may
be to use pharmacologic intervention during ex vivo
culture. Recently, retinoic acid (RA) has been described
as inhibiting IL-17 polarisation and to promote FoxP3
expression [42]. Another pharmacologic agent, already in
use, as discussed above, is rapamycin which was demon-
strated to improve suppressive activity and FoxP3 expres-
sion in ex vivo expanded human Treg, especially when
isolated with magnetic beads [24].
Introduction of additional factors to the in vitro Treg
cultures that maintain FoxP3 expression in ex vivo
manipulated cells appears to be an attractive way of
ensuring their effectiveness and safety for the patient.
Additionally, obtaining cells with higher per cell activity
would potentially allow a significant reduction in the
number of Treg required for each clinical application.
Cancer and infection immunity
One of the concerns regarding the application of Treg in
transplant recipients is the possibility of inhibition of anti-
tumour and antiviral immunity. Theoretically, infusion
with large numbers of potent suppressor cells may present
a serious obstacle to the induction of effective immune
responses towards infectious pathogens and a reduction in
immune surveillance against tumour cells. As is often the
case with the immune system, reality may not fit with
theoretical predictions. For example, in vivo ablation of
Treg was recently demonstrated to lead to accelerated
fatal infection during mucosal herpes simplex virus in-
fection, suggesting that in some situations Treg facilitate
early protective responses to local viral infection [43].Current Opinion in Immunology 2010, 22:662–668
666 Immunogenetics and transplantationNotably, it has also been demonstrated in mice that
antigen-specific, in vivo induced Treg which were able
to induce tolerance in primary and secondary allograft
recipients did not affect anti-influenza response even
when bystander regulation was deliberately induced [44].
Numerous studies suggest that the accumulation of Treg
at tumour sites may affect anti-tumour immunity, there-
fore infusion of substantial numbers of Treg may particu-
larly influence the response towards already existing early
tumours. Notably, high numbers of Treg in the blood
have been recently associated with increased risk of new
tumour development in kidney transplant recipients with
non-malignant squamous cell carcinoma [45]. On the
other hand, immunosuppressive agents currently being
used are themselves associated with increased risk of
cancer [46]. Therefore, careful screening and monitoring
of transplant recipients eligible for Treg cellular therapy
should be performed before and after infusion in any pilot
clinical study.
Conclusion
Recent progress in understanding Treg biology and the
development of experimental mouse models has high-
lighted potential avenues in the translation of research-
based knowledge to the clinic. Insights into the biological
role of FoxP3, the effects of immunosuppression on Treg
and new protocols to expand or induce Treg provide a
knowledge base for developing clinical strategies to
achieve long-term graft survival without life-long immu-
nosuppression.
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